| Filed On | Filing |
|---|---|
| 30 May 2024 | Form 3: PharmaCyte Biotech, Inc., 10% owner · Q/C Technologies Inc |
| 28 Nov 2023 | Form 3: PharmaCyte Biotech, Inc., 10% owner · Femasys Inc |
| 30 Dec 2022 |
Form 3: Walker Wayne Remell, Director
No securities owned |
| 16 Nov 2022 |
Form 3: Weinstein Robert, Director
No securities owned |
| 24 Aug 2022 |
Form 3: Allen Daniel, Director
Holds 260,000 shares of Common Shares |
| 23 Aug 2022 |
Form 3: Schechter Jonathan, Director
Holds 50,000 shares of Common Stock |
| 23 Aug 2022 |
Form 3: Stover Jack E, Director
No securities owned |
| 23 Aug 2022 |
Form 3: Silverman Joshua, Director
Holds 50,000 shares of Common Stock |
| 23 Aug 2022 |
Form 3: Farb Daniel Stuart, Director
Holds 714,570 shares of Common Stock |
| 11 Apr 2022 |
Form 3: Loehr Matthias, Director
Holds 3,004 shares of Common Stock |
| 03 Sep 2021 |
Form 3: Trujillo Carlos, Director
Holds 8,800 shares of Common Stock |
| 31 Aug 2021 |
Form 3: Waggoner Kenneth L., Director
Holds 20,600 shares of Common Stock |
| 31 Aug 2021 |
Form 3: Yuen Thomas C K, Director
Holds 1,667 shares of Common Stock |
| 31 Aug 2021 |
Form 3: Crabtree Gerald W, Director
Holds 11,200 shares of Common Stock |
| 20 Aug 2021 |
Form 3: Liquard Thomas, Director
Holds 1,667 shares of Common Stock |
| 20 Aug 2021 |
Form 3: Tong Raymond Cf, Director
Holds 1,333 shares of Common Stock |
| 20 Aug 2021 |
Form 3: Abecassis Michael M, Director
Holds 1,667 shares of Common Stock |
| 30 Mar 2009 |
Form 3: Schmieg Martin, Director
Holds 425,328 shares of Common stock, par value $0.0001 |
| 30 Mar 2009 |
Form 3: Barnes Marylew, Director
Holds 121,805 shares of Common stock, par value $0.0001 |
Loading...